Autism Committee Schedules July Public Meeting
Published Date: 7/7/2026
Notice
Summary
The Interagency Autism Coordinating Committee is holding a free, public meeting on July 31, 2026, to talk about autism research and services. You can join in person or online, but if you want to attend in person, you need to register ahead of time. The committee also invites public comments by July 17, giving everyone a chance to share their thoughts and help shape autism support.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Disability accommodations and captioning provided
Closed captioning will be provided through the NIH videocast, and individuals needing special assistance (for example, sign language interpreters) must request accommodations from the Contact Person at least seven (7) business days before the meeting.
Free hybrid public meeting available
The Interagency Autism Coordinating Committee will hold a free public meeting on July 31, 2026, from 9:00 a.m. to 5:00 p.m. ET that you can watch live online via the NIH Videocast. In-person attendance is allowed but requires advanced registration and seating is first-come, first-served at the Rockville, MD location.
In-person security and registration requirements
If you plan to attend in person, you must pre-register and complete a check-in process on arrival, and present a valid ID such as a REAL ID, U.S. passport, or proof of legal U.S. residency. Non-U.S. persons must pre-register at least 10 business days in advance and wait for approval to attend.
Public comment rules and deadline
The IACC is accepting written and oral/virtual public comments; written comments are due by July 17, 2026, at 5:00 p.m. ET. A limited number of ~3-minute oral/virtual comment slots are available; priority for slots goes to individuals and organizations that have not previously provided comments in the current calendar year.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2026-13713, Self-Regulatory Organizations; Financial Industry Regulatory Authority, Inc.; Notice of Partial Amendment No. 1 to Proposed Rule Change To Amend FINRA Rule 2210 (Communications With the Public)
FINRA wants to update its rules to let financial firms share predictions about investment returns when talking to the public, but only if they follow certain safety steps. This change affects anyone in the finance world who communicates about investments and aims to make info clearer and more honest. The SEC is reviewing these updates, with decisions and possible money impacts expected soon.
Next: 2026-13717, General Conference Committee of the National Poultry Improvement Plan and 47th Biennial Conference
The National Poultry Improvement Plan’s General Conference Committee is meeting August 11-14, 2026, in Salt Lake City to discuss important poultry health updates like new tests and disease news. This affects poultry farmers, state agencies, and industry folks who rely on these rules to keep flocks safe and healthy. No big costs are announced, but staying informed helps everyone protect their birds and business.